Daewoong Pharmaceutical said on the 11th that it signed a three-way memorandum of understanding (MOU) with Seers Technology and ExoSystems to jointly develop and commercialize an artificial intelligence (AI)-based bedside monitoring system.
Through this agreement, the three companies will integrate technology that collects muscle activation signals into the bedside monitoring system "thynC." They plan to build a smart ward integrated solution that can be used for sarcopenia diagnosis in clinical settings in the future.
Daewoong Pharmaceutical will promote adoption of the solution by hospitals and medical institutions and handle overall sales, including marketing activities, investor presentations, and recruiting new hospitals. Seers Technology will co-develop an integrated platform that links thynC with ExoSystems' muscle activation signal analysis solution "exoPill." ExoSystems will ensure the technical stability of the exoPill device and promote productization and commercialization for hospital deployment.
Lee Chang-jae, head of Daewoong Pharmaceutical, said, "We will continue to introduce Digital Healthcare solutions that deliver tangible value in clinical settings by combining each company's core strengths."
Lee Young-shin, head of Seers Technology, said, "Based on collaboration with ExoSystems, we will pursue a well-designed business model and deliver tangible results in clinical settings next year."
Lee Hoo-man, head of ExoSystems, said, "We expect this collaboration to mark meaningful progress in applying our technology to real-world medical environments," adding, "We will continue to expand into more disease areas."